Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade
about
The tumor suppressor hTid1 inhibits STAT5b activity via functional interactionMechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cellsMast cell homeostasis and the JAK-STAT pathwaySuppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinasesCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsSTAT5 in hematopoietic stem cell biology and transplantationThe PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsHow Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyStat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformationTyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.Role of intracellular tyrosines in activating KIT-induced myeloproliferative diseasePTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeabilityBortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderOncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia.Surveillance strategies for gastrointestinal stromal tumors.Indolent systemic mastocytosis limited to the bone: a case report and review of the literature.STAT signaling in the pathogenesis and treatment of myeloid malignancies.Oxidative metabolism in cancer: A STAT affair?STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia.Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization.The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.AXL regulates mesothelioma proliferation and invasiveness.Targeted Treatment Options in Mastocytosis.Acetylation and sumoylation control STAT5 activation antagonistically.Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosisThe inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells
P2860
Q24308570-EFA945CA-ABDF-4DBD-AFA2-07AA47D83C77Q24313261-418FDA77-4C30-4BC3-98D0-D05C644C532FQ24632515-E7AD027B-B2D3-41D6-A717-38F35F057B77Q24656365-45C92907-C03C-43B8-84D9-DA812076AB15Q26778929-4DC01BDC-5826-4645-AB3E-358E965E0D2DQ27022428-61FB0652-7E2D-4172-834C-028D9AF87A2DQ28480417-D5BA4DA4-2568-48AE-AE97-673A5A1D429CQ28551904-B9D93710-99BF-4212-84A4-7ED79BEDA4F0Q33423072-FA66D3CE-8FD1-48CE-866C-08175F8E87B8Q34124973-609BD74E-AF32-43BD-9D8F-42B91967C291Q34495630-FE2213DC-9429-4FCB-845C-C6F58F411F46Q35230318-344C0DE0-19AA-4CC5-97A7-E9B353F06F5EQ35553313-56C0FCD1-6099-429C-89C2-D8F62F315670Q35786902-17BDCCB7-B7B3-444D-80D6-ACB2F33FB6F1Q35956625-03CA1528-B5AF-4519-8964-6FAAF17D77E2Q36210845-07B6E09B-474A-4B6A-B346-D78922EC8990Q37262426-CDBB6762-8D7C-4803-940C-00FADFBBDC99Q37460343-9AB394AA-11AA-439F-B4A9-690884B34098Q37462729-0C39CEEE-9646-40BF-AB78-6CC303BF24B2Q37810130-EA819DDA-7C62-4FDA-943C-D815E3E461C7Q37861191-51C249F0-9800-4534-914E-53CB2FEC6C4FQ37954209-E2705092-78CB-4E9F-9FB2-3A15763B9F01Q38125573-43503169-3860-4BFF-ADB4-AC9B5EAF5F09Q38140880-D60BA777-44FD-4A1F-A4E1-2B8566ED1ED5Q38177820-D63A35AF-C51B-4E27-9A13-CEE89DE8C34BQ38177821-2C9A1AAC-53E7-4BEA-96C6-E3FD9C8F64D5Q38193659-330D08A7-1EC7-416F-B6BA-EFF4C9718F16Q38370943-33D1C378-7927-40AC-89FC-B95895A918A9Q38724800-1EFECDE6-E6E3-4C5E-A849-883346918D2FQ38773224-77E3634D-6AE0-43C4-9F43-25A1FB119577Q38777126-084ECDCF-96CE-4E65-A4DD-B0564B642CCCQ38810236-A9FD41EA-FBDD-43A4-9926-1B4296394115Q39064868-2C36F76C-C449-4BE0-B647-7B2D9648C93FQ39448829-B244FEB7-A39E-45C1-8891-10110AE96262Q39615506-4A4B5413-A4D7-4C2E-83BC-3A3A83D2BAC2Q39623714-9DCAF5E1-60A1-4E2D-93B3-4C404EFBE76CQ41061871-6C15C0B3-314C-4322-811A-3D6F212C6873Q41390061-26BB8478-5F96-4223-B73B-FBC123C1489DQ42045097-3C4ED572-07FD-4952-B1E9-BFDD5F2671E5Q42117814-713648A5-6CB4-417F-90F6-26C0710BDAC9
P2860
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@en
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@nl
type
label
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@en
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@nl
prefLabel
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@en
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@nl
P2093
P2860
P50
P1433
P1476
Oncogenic Kit controls neoplas ...... 5/PI3-kinase signaling cascade
@en
P2093
Cédric Boudot
Fabrice Gouilleux
Jean Gondry
Karoline Sonneck
Katrin Friedbichler
Kaïss Lassoued
Laurence Bénit
Marc Kerenyi
Noria Harir
Peter Valent
P2860
P304
P356
10.1182/BLOOD-2007-09-115477
P407
P577
2008-06-25T00:00:00Z